1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hepatitis C-API Insights, 2015

Hepatitis C-API Insights, 2015

  • April 2015
  • -
  • Delve Insight
  • -
  • 60 pages

Summary

DelveInsight’s, Hepatitis C-API Insights, 2015,report provides Hepatitis C drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Hepatitis C. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Hepatitis C drugs till 2016.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global Market therapeutics scenario for Hepatitis C.
• A review of the marketed products under prescription for Hepatitis C, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Hepatitis C with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Hepatitis C drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Hepatitis C drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2012-2016.

Reasons to Buy

• Evaluate the marketing status and exclusivity details of Hepatitis C key products to exploit opportunities for generic drug development opportunities.
• Key players in the pharmaceutical industry.
•Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hepatitis C.
• API intelligence over marketed drugs for Hepatitis C and gaining primary intelligence over active ingredients manufacturers across the globe.
• Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Hepatitis C-API Insights, 2015
Table of Contents
• Indication Overview
• Marketed Drugs Assessment
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• The API Manufacturers by the United States Drug Master File (US DMF) Status
• The API Manufacturers by the US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figures (2012-2016)
• Marketed Drugs Information
• Drugs Description
• Global Active Pharmaceutical Manufacturers
• Approval Status
• Patent and Exclusivity Details
• Company Overview
• Discontinued Drugs Information

List of Tables

Hepatitis C Therapeutic Market, US, Marketed Drugs by Application Type, 2015
Hepatitis C Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015
Hepatitis C Therapeutic Market, US, (Year), 2015
Hepatitis C Marketed Drugs, API Manufacturers by US DMF Status, 2015
Hepatitis C Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Hepatitis C Therapeutic Market, Global Sales (in million USD), 2015
Hepatitis C Marketed Drugs, API Manufacturers, Global, 2015
Discontinued Drugs for Hepatitis C, 2015

List of Figures

Hepatitis C Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015
Hepatitis C Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015
Hepatitis C Therapeutic Market, US, (Year), 2015
Hepatitis C Marketed Drugs, API Manufacturers by US DMF Status (%), 2015
Hepatitis C Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Hepatitis C Therapeutic Market, Global Sales (in million USD), 2015
Hepatitis C Marketed Drugs, Patent/Exclusivity Expiry (Year), 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...

Epiomic Epidemiology Series: Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Chronic Hepatitis C in 12 Major Markets Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, ...

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

In this report, Persistence Market Research (PMR) offers an eight year forecast of the global hepatitis C treatment market between 2016 and 2024. The current study reveals the market trends and market ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.